The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)‐Endoxifen in Breast Cancer-Reference-Cited by-同舟云学术

The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)‐Endoxifen in Breast Cancer

Published:2019-11-09 Issue:2 Volume:13 Page:284-292
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Nardin Jeanine Marie¹²³^ORCID,Schroth Werner⁴⁵,Almeida Thais Abreu⁶,Mürdter Thomas⁴⁵,Picolotto Solane⁷,Vendramini Evelyn Castillo Lima⁷^ORCID,Hoppe Reiner⁴⁵,Kogin Jenifer Primon²^ORCID,Miqueleto Diandra²^ORCID,Moraes Silvia Dark Robaskievicz²,Schwab Matthias⁴⁸⁹¹⁰,Pecoits‐Filho Roberto Flavio³^ORCID,Brauch Hiltrud⁴⁵⁹¹⁰^ORCID,Casali‐da‐Rocha José Claudio³¹¹^ORCID

Affiliation:

1. Clinical Research Department Erasto Gaertner Hospital Curitiba Brazil

2. School of Health Science UniBrasil Curitiba Brazil

3. Pontifical Catholic University of Parana Curitiba Brazil

4. Dr. Margarete Fischer‐Bosch-Institute of Clinical Pharmacology Stuttgart Germany

5. University of Tuebingen Tuebingen Germany

6. Clinical Oncology Department Erasto Gaertner Hospital Curitiba Brazil

7. Pharmacy Department Erasto Gaertner Hospital Curitiba Brazil

8. Departments of Clinical Pharmacology, Pharmacy and Biochemistry University of Tuebingen Tuebingen Germany

9. German Cancer Consortium (DKTK) German Cancer Research Center (DKFZ) Heidelberg Germany

10. iFIT Cluster of Excellence University of Tuebingen Tuebingen Germany

11. Department of Oncogenetics Erasto Gaertner Hospital Curitiba Brazil

Funder

Robert Bosch Stiftung

Deutsche Forschungsgemeinschaft

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12707

Reference52 articles.

1. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

2. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

3. World Health Organization.Adherence to Long‐Term Therapies: Evidence for Action(World Health Organization Geneva Switzerland 2003).

4. Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings

5. Adjuvant Hormonal Therapy Use Among Insured, Low-Income Women With Breast Cancer

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adherence, clinical benefits, and adverse effects of endocrine therapies among women with nonmetastatic breast cancer in developing countries: A systematic review and meta‐analysis;Cancer;2024-09-05

2. Genotipy CYP2D6*3, *4, *6 i gipertrofiya endometriya u bol'nyh rakom molochnoj zhelezy na fone terapii tamoksifenom;Вестник Российского государственного медицинского университета;2023-10

3. CYP2D6*3, *4, *6 genotypes and endometrial thickness in patients with breast cancer during tamoxifen therapy;Bulletin of Russian State Medical University;2023-10

4. Cross‐Ancestry Genome‐Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations;Clinical Pharmacology & Therapeutics;2023-01-31

5. Influence of CYP2D6, CYP2C19 and CYP3A5 polymorphisms on plasma levels of tamoxifen metabolites in Algerian women with ER+ breast cancer;Egyptian Journal of Medical Human Genetics;2022-08-14